Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:21 Issue:1 Number:3 ISSN#:2563-5476
RCT
ACE Report #13446
Ace Report Cover Arthroplasty

Similar Clinical Outcomes in Oral TXA vs Epsilon-Aminocaproic Acid Up to 30 Days After THA Surgery


How to Cite

OrthoEvidence. Similar Clinical Outcomes in Oral TXA vs Epsilon-Aminocaproic Acid Up to 30 Days After THA Surgery. ACE Report. 2021;21(1):3. Available from: https://myorthoevidene.com/AceReport/Report/13446

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Tranexamic acid versus aminocapróic acid in multiple doses via the oral route for the reduction of postoperative bleeding in total primary hip arthroplasty: a prospective, randomized, double-blind, controlled study

Blood Coagul Fibrinolysis. 2021 Mar 1;32(2): 132-139.

Contributing Authors: R Morales-Avalos T Ramos-Morales JA García-Pedro AM Espinoza-Galindo C Acosta-Olivo M Morcos-Sandino HNG Silva-Ramos VM Peña-Martínez RA Rodríguez-Torres F Vilchez-Cavazos

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and two patients scheduled to undergo an elective cementless primary unilateral total hip arthroplasty (THA) to treat either osteoarthritis, osteonecrosis of femoral head or developmental dysplasia of hip were randomized to receive either oral tranexamic acid (TXA) or oral epsilon-aminocaproic acid (EACA) which were both administered pre-operatively (2h pre-incision) and at 6 and 12 ho...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE